Trump Administration Reclassifies Medical Marijuana, Paving the Way for Greater Accessibility

Thu Apr 23 2026 14:28:14 GMT+0000 (Coordinated Universal Time)

In a historic move, acting Attorney General Todd Blanche has reclassified state-licensed medical marijuana from Schedule I to Schedule III, facilitating easier access and tax benefits for medical marijuana producers.

The Trump administration has officially reclassified licensed medical marijuana as a less-dangerous drug, shifting it from Schedule I to Schedule III. This change, spearheaded by acting Attorney General Todd Blanche, promises to ease regulations surrounding medical marijuana and provide tax benefits for businesses operating in this space. While it does not legalize marijuana, it marks a significant policy shift amidst a wider context of evolving cannabis legislation across the United States.

In a historic move signaling a shift in federal cannabis policy, acting Attorney General Todd Blanche formally reclassified state-licensed medical marijuana from Schedule I to Schedule III. This change signifies a major step for advocates who have long argued against treating cannabis as comparable to dangerous drugs like heroin.

The new classification, signed on Thursday, allows licensed medical marijuana operators to benefit from major tax breaks, alleviating some barriers to cannabis research and fostering improved access for patients. While it does not legalize marijuana, the shift eases regulations surrounding its use in medical contexts.

Blanche emphasized that this decision aligns with President Trump’s previously stated commitment to broadening medical treatment options for Americans. “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,” Blanche stated.

The order also intends to create a streamlined system for medical marijuana producers and distributors to register with the Drug Enforcement Administration (DEA). It is seen as legitimizing medical marijuana frameworks established across 40 states that have already implemented such systems.

Despite the advancement in cannabis regulations, the order does not extend to non-medical marijuana or marijuana products not regulated by state medical programs, keeping much of the federal prohibition intact. Critics of the current cannabis landscape express concerns that strong marijuana products need more extensive oversight and research.

While this administrative move may alter operations in states with existing recreational marijuana markets, many Republican lawmakers still oppose loosening cannabis restrictions. Underlining the complexity of this issue are Trump’s simultaneous efforts to combat drug trafficking, focusing on particularly dangerous substances like fentanyl.

The transition to Schedule III may reflect a growing acceptance of medical marijuana and foster ongoing discussions regarding its legalization and regulation at a federal level.